Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
ACADIA Pharmaceuticals is a commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, with its lead product NUPLAZID (pimavanserin) approved for Parkinson's disease psychosis and dementia-related psychosis. The company generates revenue primarily from US commercial sales of NUPLAZID while advancing a pipeline targeting neuropsychiatric and neurological conditions. With 91.5% gross margins and recent profitability inflection (24% operating margin), ACADIA has transitioned from development-stage biotech to profitable specialty pharma.
ACADIA operates a specialty pharmaceutical model with direct sales force targeting psychiatrists, neurologists, and long-term care facilities. Revenue derives from branded prescription drug sales through US commercial channels (specialty pharmacies, retail, mail-order). Pricing power stems from limited competition in niche CNS indications with high unmet need - NUPLAZID is the only FDA-approved treatment for PDP. The 91.5% gross margin reflects typical branded pharma economics with low manufacturing costs relative to pricing. Commercial infrastructure is already built, allowing high incremental margins on volume growth and label expansions.
NUPLAZID prescription volume trends and market share in PDP and DRP indications
Clinical trial readouts and regulatory milestones for pipeline programs (Phase 3 data, FDA submissions)
Payer coverage decisions and reimbursement dynamics for NUPLAZID in expanded indications
Competitive threats from generic challenges or alternative CNS therapies entering development
Business development activity including potential licensing deals or acquisition interest
Patent expiration risk for NUPLAZID (composition of matter patents expire 2027-2030 depending on jurisdiction) could enable generic competition and revenue erosion without successful pipeline progression
Regulatory scrutiny of CNS drugs following historical FDA safety concerns around antipsychotics in elderly populations could impact label expansion opportunities or require additional post-marketing studies
Reimbursement pressure from Medicare negotiations under Inflation Reduction Act provisions beginning 2026 could affect pricing power for established products
Limited product diversification creates concentration risk - NUPLAZID represents substantially all revenue with no approved second product as of February 2026
Competitive pipeline threats from larger pharma companies developing alternative mechanisms for neuropsychiatric indications could erode NUPLAZID market share
Failure to advance pipeline candidates (trofinetide for Rett syndrome, ACP-204 for schizophrenia) would leave company dependent on single product facing patent cliff
While current balance sheet is strong, sustained profitability depends on maintaining NUPLAZID revenue growth trajectory - any significant prescription volume decline would pressure margins
Pipeline development requires continued R&D investment ($150-200M annually estimated) which could consume cash if revenue growth stalls before additional products reach market
low - Prescription pharmaceutical demand for chronic neurological conditions is largely non-discretionary and insulated from economic cycles. Patients with Parkinson's disease psychosis or dementia require ongoing treatment regardless of macroeconomic conditions. However, Medicare and Medicaid reimbursement policies can be influenced by government budget pressures during recessions.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for growth-oriented biotech stocks, particularly impacting companies trading on future pipeline potential rather than current earnings. (2) Increased financing costs affect capital allocation decisions if ACADIA pursues debt financing for business development or pipeline expansion. However, with $600M+ cash position and positive operating cash flow, near-term financing needs are minimal. The 3.7x P/S multiple suggests some rate sensitivity in valuation.
Minimal - ACADIA has negligible debt (0.06 D/E ratio) and strong liquidity (3.02 current ratio). The company does not rely on credit markets for operations and generates positive free cash flow ($200M TTM). Customer credit risk is low as revenue flows through established pharmaceutical distribution channels with creditworthy intermediaries (specialty pharmacies, PBMs). Payer mix is heavily weighted toward Medicare/Medicaid with predictable reimbursement.
growth - The 31.8% revenue growth, recent profitability inflection (470% net income growth), and 16.3% one-year return attract growth investors focused on commercial-stage biotech with proven products. The 3.7x P/S and 31.4x EV/EBITDA multiples reflect growth expectations rather than value characteristics. However, the transition to sustained profitability (24% operating margin) is beginning to attract growth-at-a-reasonable-price (GARP) investors who previously avoided unprofitable biotechs. Limited dividend yield (not mentioned in fundamentals, likely zero) means income investors are not the target audience.
high - Biotech stocks typically exhibit elevated volatility driven by binary clinical trial outcomes, regulatory decisions, and patent/competitive dynamics. The -4.4% three-month and -9.4% six-month returns despite strong fundamentals illustrate sector-wide volatility. Single-product revenue concentration amplifies stock sensitivity to NUPLAZID-specific news (safety signals, competitive threats, reimbursement changes). Beta likely exceeds 1.3-1.5 relative to broader market given biotech sector characteristics and $3.9B market cap positioning in mid-cap range with less institutional ownership stability than large-cap pharma.
